Notable Reporting: Could Curis, Inc. Change Direction After Today’s Significant Decline?

Notable Reporting: Could Curis, Inc. Change Direction After Today's Significant Decline?

The stock of Curis, Inc. (NASDAQ:CRIS) is a huge mover today! About 976,834 shares traded hands or 27.81% up from the average. Curis, Inc. (NASDAQ:CRIS) has risen 110.23% since April 13, 2016 and is uptrending. It has outperformed by 106.30% the S&P500.
The move comes after 6 months negative chart setup for the $540.15 million company. It was reported on Nov, 15 by Barchart.com. We have $3.32 PT which if reached, will make NASDAQ:CRIS worth $27.01M less.

Curis, Inc. (NASDAQ:CRIS) Ratings Coverage

Out of 4 analysts covering Curis (NASDAQ:CRIS), 3 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 75% are positive. Curis has been the topic of 6 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The company was downgraded on Monday, September 21 by Zacks. The stock has “Buy” rating given by TH Capital on Monday, November 9. The rating was initiated by FBR Capital on Tuesday, August 11 with “Outperform”. The stock has “Buy” rating given by Roth Capital on Monday, November 9. The firm has “Hold” rating given on Tuesday, September 1 by Zacks.

According to Zacks Investment Research, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.”

Insitutional Activity: The institutional sentiment increased to 1.78 in 2016 Q2. Its up 0.88, from 0.9 in 2016Q1. The ratio is positive, as 8 funds sold all Curis, Inc. shares owned while 15 reduced positions. 11 funds bought stakes while 30 increased positions. They now own 67.45 million shares or 4.41% less from 70.56 million shares in 2016Q1.
Weiss Multi has 0.02% invested in the company for 126,846 shares. The New York-based Amalgamated National Bank has invested 0% in Curis, Inc. (NASDAQ:CRIS). Voya Investment Mgmt Ltd has invested 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS). Bridgeway Mgmt last reported 277,725 shares in the company. Teachers Advsrs holds 180,776 shares or 0% of its portfolio. Fmr Ltd Liability Corporation holds 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS) for 15.92 million shares. First Eagle Invest Mngmt Lc has 24.01M shares for 0.1% of their US portfolio. California State Teachers Retirement System, a California-based fund reported 234,079 shares. Kcg has 39,817 shares for 0% of their US portfolio. Tudor Corp Et Al accumulated 18,963 shares or 0% of the stock. Focused Wealth Mngmt reported 188,350 shares or 0.14% of all its holdings. The California-based California Employees Retirement has invested 0% in Curis, Inc. (NASDAQ:CRIS). Moreover, Point72 Asset Mngmt Ltd Partnership has 0.01% invested in Curis, Inc. (NASDAQ:CRIS) for 1.10 million shares. Cornerstone Mgmt Holdings Llc last reported 0% of its portfolio in the stock. Commercial Bank Of America Corp De owns 29,930 shares or 0% of their US portfolio.

Insider Transactions: Since May 26, 2016, the stock had 0 insider purchases, and 2 sales for $51,750 net activity. KAITIN KENNETH I had sold 15,000 shares worth $26,400. GREENACRE MARTYN D sold $25,350 worth of stock.

CRIS Company Profile

Curis, Inc., incorporated on February 14, 2000, is a biotechnology company. The Firm is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment